- 2023

68th Legislature 2023 Drafter: Erin Sullivan, 406-444-3594 SB0351.003.004

1	SENATE BILL NO. 351
2	INTRODUCED BY D. ZOLNIKOV
3	
4	A BILL FOR AN ACT ENTITLED: "AN ACT REVISING LAWS RELATED TO BIOMETRIC PRIVACY;
5	CREATING THE GENETIC INFORMATION PRIVACY ACT; REQUIRING A COMPANY AN ENTITY TO
6	PROVIDE CONSUMER INFORMATION REGARDING THE COLLECTION, USE, AND DISCLOSURE OF
7	GENETIC DATA; PROVIDING FOR LIMITATIONS AND EXCLUSIONS; PROVIDING FOR ENFORCEMENT
8	AUTHORITY; AND PROVIDING DEFINITIONS."
9	
10	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MONTANA:
11	
12	NEW SECTION. Section 1. Short title. [Sections 1 through 6] may be cited as the "Genetic
13	Information Privacy Act".
14	
15	NEW SECTION. Section 2. Definitions. As used in [sections 1 through 6], unless the context clearly
16	indicates otherwise, the following definitions apply:
17	(1) "Biological sample" means any human material knows known to contain DNA, including tissue,
18	blood, urine, or saliva.
19	(2) (a) "Company" means an entity that:
20	(i) offers consumer genetic testing products or services directly to a consumer; or
21	(ii) collects, uses, or analyzes genetic data that resulted from a direct-to-consumer genetic testing
22	product or service and was provided to the company by a consumer FOR A COMMERCIAL PURPOSE.
23	(b) The term does not include an entity when it is engaged only in collecting, using, or analyzing
24	genetic data or biological samples in the context of research as defined in 45 CFR 164.501 conducted in
25	accordance with the federal policy for the protection of human research subjects under 45 CFR, part 46, the
26	good clinical practice guideline issued by the international council for harmonisation of technical requirements
27	for pharmaceuticals for human use, or the United States food and drug administration policy for the protection



- 2023

68th Legislature 2023 Drafter: Erin Sullivan, 406-444-3594 SB0351.003.004

1	o f human subjects under 21 CFR, parts 50 and 56.		
2	(3) (2)	"Consumer" means an individual who is a resident of this state.	
3	(4)	"Deidentified data" means data that:	
4	(a)	cannot be reasonably linked to an identifiable individual; and	
5	(b)	is possessed by a company that:	
6	(i)	takes administrative and technical measures to ensure that the data cannot be associated with	
7	a particular consumer;		
8	(ii)	makes a public commitment to maintain and use data in deidentified form and to not attempt to	
9	reidentify data;	and	
10	(iii)	enters a legally enforceable contractual obligation that prohibits a recipient of the data from	
11	attempting to reidentify the data.		
12	(5) (3)	"DNA" means deoxyribonucleic acid.	
13	<u>(4)</u>	"Entity" means a partnership, corporation, association, or public or private organization of any	
14	character that:		
15	<u>(a)</u>	offers consumer genetic testing products or services directly to a consumer; or	
16	<u>(b)</u>	collects, uses, or analyzes genetic data.	
17	(6) (5)	"Express consent" means a consumer's affirmative response to a clear, meaningful, and	
18	prominent notic	ce regarding the collection, use, or disclosure of genetic data for a specific purpose.	
19	(7) (6)	(a) "Genetic data" means any data, regardless of format, concerning a consumer's genetic	
20	characteristics.		
21	(b)	The term includes but is not limited to:	
22	(i)	raw sequence data that result from sequencing all or a portion of a consumer's extracted DNA;	
23	(ii)	genotypic and phenotypic information obtained from analyzing a consumer's raw sequence	
24	data; and		
25	(iii)	self-reported health information regarding a consumer's health conditions that the consumer	
26	provides to a c	ompany an entity that the company entity:	
27	(A)	uses for scientific research or product development; and	



- 2023 68th Legislature 2023

Drafter: Erin Sullivan, 406-444-3594 SB0351.003.004

1	(B)	analyzes in connection with the consumer's raw sequence data.
2	(c)	The term does not include deidentified data.
3	(8) (7)	"Genetic testing" means:
4	(a)	a laboratory test of a consumer's complete DNA, regions of DNA, chromosomes, genes, or
5	gene products	to determine the presence of genetic characteristics of a consumer; or
6	(b)	an interpretation of a consumer's genetic data.
7	(8)	"Governmental agency" means an executive, legislative, or judicial agency, department, board,
8	commission, a	uthority, institution, or instrumentality of the federal government or of a state or of a county,
9	municipality, or	other political subdivision of a state.
10	(9)	"Person" means an individual, partnership, corporation, association, business, business trust,
11	or legal represe	entative of an organization.
12	(10)	"Processor" means a person that processes genetic data on behalf of an entity pursuant to a
13	contract betwe	en the entity and the processor that prohibits the processor from retaining, using, or disclosing
14	the genetic dat	a, or any information regarding the identity of the consumer, including whether that consumer
15	has solicited or	received genetic testing, as applicable, for any purpose other than for the specific purpose of
16	performing the	services specified in the contract.
17	(11)	"Third party" means a person other than the consumer, entity, or processor.
18		
19	NEW S	SECTION. Section 3. Limitations Exceptions. (1) [Sections 1 through 6] do not apply to:
20	<u>(a)</u>	_protected health information that is collected by a covered entity or business associate as
21	those terms are	e defined in 45 CFR, parts 160 and 164, if separate informed consent related to the collection,
22	use, and disse	mination of genetic data is obtained from the consumer, parent, guardian, or power of attorney,
23	and the covere	d entity or business associate follows the policies under [sections 4(6)(a) through (6)(d)];
24	<u>(b)</u>	an entity when it is engaged only in collecting, using, or analyzing genetic data or biological
25	samples in the	context of research as defined in 45 CFR 164.501 conducted with the express consent of an
26	individual and i	n accordance with:
27	(i)	the federal policy for the protection of human research subjects under 45 CFR, part 46, the



- 2023 68th Legislature 203

68th Legislature 2023 Drafter: Erin Sullivan, 406-444-3594 SB0351.003.004

1	good clinical practice guideline issued by the international council for narmonisation of technical requirements
2	for pharmaceuticals for human use; or
3	(ii) the United States food and drug administration policy for the protection of human subjects
4	under 21 CFR, parts 50 and 56; or
5	(c) uses by a governmental agency.
6	(2) Beginning June 1, 2025, any collection, storage, use, or dissemination of genetic data by a
7	governmental agency must be performed in accordance with a specific state law or executed through a search
8	<u>warrant.</u>
9	
10	NEW SECTION. Section 4. Consumer genetic data privacy notice consent access
11	deletion destruction. To safeguard the privacy, confidentiality, security, and integrity of a consumer's
12	genetic data, a company an entity shall:
13	(1) provide clear and complete information regarding the company's entity's policies and
14	procedures for the collection, use, or disclosure of genetic data by making available to a consumer:
15	(a) a high-level privacy policy overview that includes basic, essential information about the
16	company's entity's collection, use, or disclosure of genetic data; and
17	(b) a prominent, publicly available privacy notice that includes, at a minimum, information about the
18	company's entity's data collection, consent, use, access, disclosure, transfer, security, and retention and
19	deletion practices for genetic data;
20	(2) obtain a consumer's initial express consent from a consumer, parent, guardian, or power of
21	attorney for the collection, use, or disclosure of the consumer's genetic data that:
22	(a) clearly describes the company's entity's use of the genetic data that the company entity collects
23	through the company's entity's genetic testing product or service;
24	(b) specifies the categories of individuals within the entity that have who has access to test results;
25	and
26	(c) specifies how the company entity may share the genetic data;
27	(3) if the company entity engages in any of the following, obtain a consumer's:



- 2023 68th Legislature 2023

Drafter: Erin Sullivan, 406-444-3594

1 (a) separate express consent for: 2 (i) the transfer or disclosure of the consumer's genetic data or biological sample to any person 3 third party other than the company's vendors and service providers entity's processors, including the name of 4 the third party to which the consumer's genetic data or biological sample will be transferred or disclosed with 5 the consumer's express consent; 6 the use of genetic data beyond the primary purpose of the company's entity's genetic testing (ii) 7 product or service and inherent contextual uses; or 8 (iii) the company's entity's retention of any biological sample provided by the consumer following 9 the company's entity's completion of the initial testing service requested by the consumer; 10 (b) informed express consent in accordance with the federal policy for the protection of human 11 research subjects under 45 CFR, part 46, for transfer or disclosure of the consumer's genetic data to third party 12 persons for: 13 (i) research purposes; or 14 (ii) research conducted under the control of the company entity for the purpose of publication or 15 generalizable knowledge; and 16 (c) express consent for: marketing to a consumer based on the consumer's genetic data; or 17 (i) 18 (ii) marketing by a third-party person to a consumer based on the consumer having ordered or 19 purchased a genetic testing product or service. Marketing does not include the provision of customized content 20 or offers on the websites or through the applications or services provided by the company entity with the first-21 party relationship to the customerconsumer; or 22 sale or other valuable consideration of the consumer's genetic data. (iii) 23 (4) comply with the provisions of 44-6-104 requiring a valid legal process for disclosing genetic 24 data to law enforcement or any other government agency without a consumer's express written-consent; 25 (5) develop, implement, and maintain a comprehensive security program to protect a consumer's



(6)

26

27

SB0351.003.004

genetic data against unauthorized access, use, or disclosure; and

provide a process for a consumer to:

- 2023 68th Legislature 2023

Drafter: Erin Sullivan, 406-444-3594 SB0351.003.004

1	(a)	access the consumer's genetic data;
2	(b)	delete the consumer's genetic data; and
3	<u>(c)</u>	revoke any consent provided by the consumer; and
4	(c) (d)	request and obtain the destruction of the consumer's biological sample.
5	<u>(7)</u>	GENETIC DATA OF MONTANA RESIDENTS OR BIOMETRIC DATA COLLECTED IN THE STATE MUST BE
6	STORED WITHIN	THE TERRITORIAL BOUNDARIES OF THE UNITED STATES. Genetic data and biometric samples of
7	Montana reside	ents collected in the state may not be stored within the territorial boundaries of any country
8	currently sanct	ioned in any way by the United States office of foreign asset control or designated as a foreign
9	adversary unde	er 15 CFR 7.4(a). Genetic data or biometric data of Montana residents collected in the state may
10	only be transfe	rred or stored outside the United States with the consent of the resident.
11		
12	NEW S	SECTION. Section 5. Disclosure when prohibited when written express consent
13	required. (1) T	he disclosure of genetic data pursuant to [sections 1 through 6] must comply with all state and
14	federal laws for	the protection of privacy and security.
15	(2)	[Sections 1 through 6] may not apply to protected health information that is collected by a
16	covered entity	or business associate governed by the privacy, security, and breach notification rules issued by
17	the:	
18	(a)	United States department of health and human services, 45 CFR, parts 160 and 164,
19	established pur	suant to the federal Health Insurance Portability and Accountability Act of 1996; and
20	(b)	federal Health Information Technology for Economic and Clinical Health Act of 2009.
21	(3) (2)	Notwithstanding any other provisions in [section 4], a company an entity may HAS THE SOLE
22	AUTHORITY TO n	nay not disclose a consumer's genetic data to any entity offering health insurance, life insurance,
23	or long-term ca	re insurance, or to any employer of the consumer without the consumer's written express
24	consent.	
25		
26	NEW S	SECTION. Section 6. Enforcement. (1) The attorney general may has the sole authority to
27	enforce [section	ns 1 through 61.



- 2023 68th Legislature 2023

Drafter: Erin Sullivan, 406-444-3594 SB0351.003.004

1	(2)	The attorney general may initiate a civil enforcement action against a person for violation of
2	[sections 1 thro	ough 6].
3	(3)	In an action to enforce [sections 1 through 6], the attorney general may recover:
4	(a)	actual damages to the consumer;
5	(b)	costs;
6	(c)	reasonable attorney fees; and
7	(d)	\$2,500 for each violation of [section 4].
8		
9	NEW S	SECTION. Section 7. Codification instruction. [Sections 1 through 6] are intended to be
10	codified as an	integral part of Title 30, and the provisions of Title 30 apply to [sections 1 through 6].
11		- END -

